[go: up one dir, main page]

DK1011653T3 - Anvendelse af xanthophyller i medikamenter til forbedring af varigheden af muskelfunktion eller behandling af muskelforstyrrelser eller -lidelser - Google Patents

Anvendelse af xanthophyller i medikamenter til forbedring af varigheden af muskelfunktion eller behandling af muskelforstyrrelser eller -lidelser

Info

Publication number
DK1011653T3
DK1011653T3 DK98943128T DK98943128T DK1011653T3 DK 1011653 T3 DK1011653 T3 DK 1011653T3 DK 98943128 T DK98943128 T DK 98943128T DK 98943128 T DK98943128 T DK 98943128T DK 1011653 T3 DK1011653 T3 DK 1011653T3
Authority
DK
Denmark
Prior art keywords
disorders
muscle
duration
treatment
xanthophylls
Prior art date
Application number
DK98943128T
Other languages
English (en)
Inventor
Ake Lignell
Original Assignee
Bioprocess Sweden Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20408142&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1011653(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bioprocess Sweden Ab filed Critical Bioprocess Sweden Ab
Application granted granted Critical
Publication of DK1011653T3 publication Critical patent/DK1011653T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Fodder In General (AREA)
DK98943128T 1997-09-04 1998-08-26 Anvendelse af xanthophyller i medikamenter til forbedring af varigheden af muskelfunktion eller behandling af muskelforstyrrelser eller -lidelser DK1011653T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9703191A SE512531C2 (sv) 1997-09-04 1997-09-04 Användning av åtminstone en typ av xantofyller för framställning av ett läkemedel för profylaktisk och/eller terapeutisk förbättring av muskelfunktionsdurationen hos däggdjur och/eller behandling av muskelstörningar eller - sjukdomar hos däggdjur
PCT/SE1998/001526 WO1999011251A1 (en) 1997-09-04 1998-08-26 Medicament for improvement of duration of muscle function or treatment of muscle disorders or diseases

Publications (1)

Publication Number Publication Date
DK1011653T3 true DK1011653T3 (da) 2003-05-26

Family

ID=20408142

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98943128T DK1011653T3 (da) 1997-09-04 1998-08-26 Anvendelse af xanthophyller i medikamenter til forbedring af varigheden af muskelfunktion eller behandling af muskelforstyrrelser eller -lidelser

Country Status (13)

Country Link
US (1) US6245818B1 (da)
EP (1) EP1011653B1 (da)
JP (1) JP3660244B2 (da)
AT (1) ATE230985T1 (da)
AU (1) AU727349B2 (da)
CA (1) CA2299366C (da)
DE (1) DE69810784T2 (da)
DK (1) DK1011653T3 (da)
ES (1) ES2191329T3 (da)
NO (1) NO20001087L (da)
PL (1) PL338982A1 (da)
SE (1) SE512531C2 (da)
WO (1) WO1999011251A1 (da)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0001071D0 (sv) * 2000-03-27 2000-03-27 Astacarotene Ab Method of inhibiting the expression of inflammatory cytokines and chemokines
US7078040B2 (en) 2000-03-27 2006-07-18 Fuji Chemical Industry Co., Ltd. Method of inhibiting the expression of inflammatory cytokines and chemokines
SE0003186D0 (sv) * 2000-09-07 2000-09-07 Astrazeneca Ab New process
US6900324B2 (en) 2000-09-07 2005-05-31 Astrazeneca Ab Process for preparing a substituted imidazopyridine compound
US7763649B2 (en) 2002-07-29 2010-07-27 Cardax Pharmaceuticals, Inc. Carotenoid analogs or derivatives for controlling connexin 43 expression
US20050004235A1 (en) * 2002-07-29 2005-01-06 Lockwood Samuel Fournier Carotenoid analogs or derivatives for the inhibition and amelioration of liver disease
US20050143475A1 (en) * 2002-07-29 2005-06-30 Lockwood Samuel F. Carotenoid analogs or derivatives for the inhibition and amelioration of ischemic reperfusion injury
US7723327B2 (en) 2002-07-29 2010-05-25 Cardax Pharmaceuticals, Inc. Carotenoid ester analogs or derivatives for the inhibition and amelioration of liver disease
US20050026874A1 (en) * 2002-07-29 2005-02-03 Lockwood Samuel Fournier Carotenoid ether analogs or derivatives for the inhibition and amelioration of liver disease
US7521584B2 (en) 2002-07-29 2009-04-21 Cardax Pharmaceuticals, Inc. Carotenoid analogs or derivatives for the inhibition and amelioration of disease
US7345091B2 (en) 2002-07-29 2008-03-18 Cardax Pharmaceuticals, Inc. Carotenoid ether analogs or derivatives for the inhibition and amelioration of disease
US20050148517A1 (en) * 2002-07-29 2005-07-07 Lockwood Samuel F. Carotenoid ether analogs or derivatives for controlling connexin 43 expression
US7375133B2 (en) 2002-07-29 2008-05-20 Cardax Pharmaceuticals, Inc. Pharmaceutical compositions including carotenoid ether analogs or derivatives for the inhibition and amelioration of disease
US20050059659A1 (en) * 2002-07-29 2005-03-17 Lockwood Samuel Fournier Carotenoid analogs or derivatives for controlling C-reactive protein levels
US7320997B2 (en) 2002-07-29 2008-01-22 Cardax Pharmaceuticals, Inc. Pharmaceutical compositions including carotenoid ester analogs or derivatives for the inhibition and amelioration of disease
US20050049248A1 (en) * 2002-07-29 2005-03-03 Lockwood Samuel Fournier Carotenoid ether analogs or derivatives for controlling C-reactive protein levels
US20050059635A1 (en) * 2002-07-29 2005-03-17 Lockwood Samuel Fournier Carotenoid ester analogs or derivatives for controlling C-reactive protein levels
EP2392562B1 (en) * 2002-07-29 2018-03-07 Cardax Pharma, Inc. Structural carotenoid analogs for the inhibition and amelioration of disease
AU2002329108A1 (en) * 2002-09-03 2004-03-29 Centro De Investigacion En Alimentacion Y Desarrollo A.C. Method of preparing chitosan microcapsules of astaxanthin and product thus obtained
US8034372B2 (en) * 2003-03-05 2011-10-11 Nestec, Ltd. Dietary supplement for athletic pets
US7619059B2 (en) 2003-07-29 2009-11-17 Life Technologies Corporation Bimolecular optical probes
CA2445420A1 (en) 2003-07-29 2005-01-29 Invitrogen Corporation Kinase and phosphatase assays
US7727752B2 (en) 2003-07-29 2010-06-01 Life Technologies Corporation Kinase and phosphatase assays
WO2005041961A1 (en) * 2003-11-03 2005-05-12 Astrazeneca Ab Imidazo [1,2-a] pyridine derivatives for the treatment of silent gastro-esophageal reflux
SE0303451D0 (sv) * 2003-12-18 2003-12-18 Astrazeneca Ab New compounds
ES2587652T3 (es) 2004-02-04 2016-10-26 Fuji Chemical Industry Co., Ltd. Astaxantina para mejorar la atrofia muscular
US20060058269A1 (en) * 2004-04-14 2006-03-16 Lockwood Samuel F Carotenoid analogs or derivatives for the inhibition and amelioration of inflammation
WO2005102356A1 (en) * 2004-04-14 2005-11-03 Hawaii Biotech, Inc. Carotenoid analogs or derivatives for the inhibition and amelioration of inflammation
US20060155150A1 (en) * 2004-10-01 2006-07-13 Lockwood Samuel F Methods for the synthesis of lutein
JP5196708B2 (ja) * 2005-02-04 2013-05-15 富士化学工業株式会社 アスタキサンチン及び／又はそのエステルを有効成分とする筋萎縮改善剤及び飲食物
US20060270590A1 (en) 2005-03-29 2006-11-30 Lockwood Samuel F Reduction in complement activation and inflammation during tissue injury by carotenoids, carotenoid analogs, or derivatives thereof
US20090297492A1 (en) * 2008-05-30 2009-12-03 Yamaha Hatsudoki Kabushiki Kaisha Method for Improving Cognitive Performance
US10867701B1 (en) 2010-06-28 2020-12-15 Heinrich Anhold System and method for optimizing patient-specific intervention strategies using point of care diagnostics
JP5924592B2 (ja) * 2013-04-30 2016-05-25 株式会社ダイセル 抗疲労用組成物
CN112057420A (zh) * 2020-09-21 2020-12-11 中国科学院烟台海岸带研究所 一种虾青素喷剂及其制备方法、使用方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2558372B1 (fr) 1984-01-25 1987-08-07 Oreal Composition medicamenteuse pour le traitement de l'acne
JP2619491B2 (ja) 1988-08-11 1997-06-11 サントリー株式会社 アスタキサンチン含有組成物
JPH0665033A (ja) 1992-08-11 1994-03-08 Lion Corp 口腔用組成物
IL110139A0 (en) 1993-06-28 1994-10-07 Howard Foundation Pharmaceutically-active antioxidants
CA2210957A1 (en) 1995-02-03 1996-08-08 Basf Aktiengesellschaft The use of carotenoids for producing drugs for the treatment of dermatoses
JPH09124470A (ja) * 1995-10-26 1997-05-13 Suntory Ltd 抗ストレス組成物

Also Published As

Publication number Publication date
US6245818B1 (en) 2001-06-12
NO20001087D0 (no) 2000-03-02
WO1999011251A1 (en) 1999-03-11
CA2299366C (en) 2008-04-22
SE9703191D0 (sv) 1997-09-04
DE69810784D1 (de) 2003-02-20
EP1011653A1 (en) 2000-06-28
SE9703191L (sv) 1999-03-05
AU9098998A (en) 1999-03-22
CA2299366A1 (en) 1999-03-11
ES2191329T3 (es) 2003-09-01
DE69810784T2 (de) 2003-11-13
JP2001514215A (ja) 2001-09-11
SE512531C2 (sv) 2000-03-27
JP3660244B2 (ja) 2005-06-15
AU727349B2 (en) 2000-12-14
EP1011653B1 (en) 2003-01-15
NO20001087L (no) 2000-03-02
ATE230985T1 (de) 2003-02-15
PL338982A1 (en) 2000-12-04

Similar Documents

Publication Publication Date Title
DK1011653T3 (da) Anvendelse af xanthophyller i medikamenter til forbedring af varigheden af muskelfunktion eller behandling af muskelforstyrrelser eller -lidelser
AU1534699A (en) Osmotic dosage form comprising first and second coats
GEP20022783B (en) Method of Preventing and Delaying Onset of Alzheimer's Disease and Composition Therefor
DK0627933T3 (da) Bystander-suppression af autoimmune sygdomme
ES2162615T3 (es) Metodo para tratar o prevenir diabetes de tipo 1 mediante la administracion oral de insulina.
ATE321529T1 (de) Dosierungsform für eine verzögerte und zunehmende wirkstoffsfreisetzung
BG102733A (en) New substituted cyclic amino acids as pharmaceutical forms
WO2003028757A1 (fr) Nouvelle methode pour induire des lymphocytes t specifiques d'antigenes
DE69331409D1 (de) Oral 1alpha-hydroxyprevitamin d
HUP0203084A2 (en) Use of baff receptor (bcma) as an immunoregulatory agent
AU3040995A (en) Treatment of autoimmune diseases by oral administration of autoantigens
ES2143539T3 (es) Uso de un agente fotosensibilizador.
ATE234602T1 (de) Verabreichungsform zur abgabe von steigenden wirkstoffdosen
BR9811086A (pt) Utilização de preparados de eritropoietina e ferro, processo para a produção de um preparado de combinação farmacêutica e embalagem unitária farmacêutica
WO1995013071A3 (en) Treatment of immunoregulatory disorders
ATE234082T1 (de) Adenosin enthaltendes arzneimittel
DK0714304T3 (da) Terapeutisk system til behandling af psoriasis
FI913100A0 (fi) Farmaceutiska preparat.
ATE280578T1 (de) Kombination von einem den retinoinsäure metabolismus blockierenden arzneimittel und einem tocopherol
DE69133077D1 (de) Herstellung von ST1435 enthaltenden pharmazeutischen Zusammensetzungen zur topischen Verwendung
ES2059312T3 (es) Medicamento que puede administrarse por via nasal, procedimiento para su preparacion y su aplicacion.
AR002724A1 (es) Peptido purificado fisiologicamente activo, sales de adicion de acido y sales de bases de dicho peptido, formas de dosificacion oral, intra-traqueal ynasal que comprenden a dicho peptido, formulacion farmaceutica que comprende a dicho peptido, usos de dicho peptido, metodo para la preparacion de dicha
EP1050309A4 (en) NEUROTROPHIC FACTOR SECRETION PROMOTERS
EA199800770A1 (ru) Лекарственный препарат для терапевтического лечения вирусного гепатита
DK0927031T3 (da) Farmaceutisk sammensætning indeholdende nimesulid til oral admnistration